Arch Therapeutics (ARTH) Short Interest Ratio & Short Volume → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free ARTH Stock Alerts $1.16 +0.04 (+3.57%) (As of 04/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Arch Therapeutics Short Interest DataCurrent Short Volume12,400 sharesPrevious Short Volume12,400 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$24,304.00Short Interest Ratio / Days to Cover3.2Last Record DateMarch 31, 2024Outstanding Shares4,740,000 sharesPercentage of Shares Shorted0.26%Today's Trading Volume1,883 sharesAverage Trading Volume6,073 sharesToday's Volume Vs. Average31% Short Selling Arch Therapeutics ? Sign up to receive the latest short interest report for Arch Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatARTH Short Interest Over TimeARTH Days to Cover Over TimeARTH Percentage of Float Shorted Over Time Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! Arch Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202412,400 shares $24,304.00 No ChangeN/A3.2 $1.96 3/15/202412,400 shares $26,040.00 No ChangeN/A2.1 $2.10 2/29/202412,400 shares $33,480.00 -1.6%N/A1 $2.70 2/15/202412,600 shares $37,800.00 -41.4%N/A1.5 $3.00 1/15/202431,300 shares $167,455.00 No ChangeN/A1.4 $5.35 12/31/202331,300 shares $226,612.00 +3.6%N/A0.5 $7.24 Get the Latest News and Ratings for ARTH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/15/202330,200 shares $138,920.00 +1.3%N/A0.3 $4.60 11/30/202329,800 shares $178,800.00 +52.8%N/A0.3 $6.00 11/15/202319,500 shares $39,000.00 +828.6%N/A0.7 $2.00 10/31/20232,100 shares $1,995.00 No ChangeN/A0.8 $0.95 10/15/20232,100 shares $1,260.00 No ChangeN/A0.3 $0.60 9/30/20232,100 shares $2,730.00 -43.2%N/A0.6 $1.30 9/15/20233,700 shares $9,620.00 +76.2%N/A0.3 $2.60 8/31/20232,100 shares $3,087.00 -4.6%N/A1.3 $1.47 8/15/20232,200 shares $3,498.00 -12.0%N/A0.5 $1.59 7/31/20232,500 shares $5,175.00 +13.6%N/A1.8 $2.07 7/15/20232,200 shares $6,270.00 +144.4%N/A5.5 $2.85 6/30/2023900 shares $2,700.00 +800.0%N/A0.8 $3.00 6/15/2023100 shares $325.00 No ChangeN/A0.1 $3.25 5/15/2023200 shares $550.00 +100.0%N/A0.2 $2.75 4/30/2023100 shares $275.00 -80.0%N/A0.1 $2.75 4/15/2023500 shares $1,650.00 +66.7%N/A0.2 $3.30 3/31/2023300 shares $1,050.00 -40.0%N/A0.1 $3.50 3/15/2023500 shares $1,950.00 No ChangeN/A0.4 $3.90 2/28/2023500 shares $1,750.00 No ChangeN/A0.3 $3.50 1/15/20239,300 shares $322.71 No ChangeN/A0.1 $0.03 11/30/202219,700 shares $886.50 +579.3%N/A0.1 $0.05 11/15/20222,900 shares $145.00 +16.0%N/A0 $0.05 10/31/20222,500 shares $116.00 -99.0%N/A0 $0.05 10/15/2022243,200 shares $9,728.00 +2,332.0%N/A0.2 $0.04 9/30/202210,000 shares $192.00 +108.3%N/A0 $0.02 9/15/20224,800 shares $76.80 No ChangeN/A0 $0.02 8/15/2022500 shares $20.50 No ChangeN/A0 $0.04 7/15/20224,100 shares $180.40 No ChangeN/A0 $0.04 6/15/202235,100 shares $1,755.00 No ChangeN/A0.1 $0.05 5/15/20224,000 shares $320.00 No ChangeN/A0 $0.08 4/15/202216,100 shares $1,432.90 +1,912.5%N/A0.1 $0.09 3/31/2022800 shares $78.08 -46.7%N/A0 $0.10 3/15/20221,500 shares $141.00 +275.0%N/A0 $0.09 2/28/2022400 shares $39.96 -98.7%N/A0 $0.10The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! ARTH Short Interest - Frequently Asked Questions What is Arch Therapeutics' current short interest? Short interest is the volume of Arch Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 12,400 shares of ARTH short. Learn More on Arch Therapeutics' current short interest. What is a good short interest ratio for Arch Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ARTH shares currently have a short interest ratio of 3.0. Learn More on Arch Therapeutics's short interest ratio. How does Arch Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Arch Therapeutics: NeuroMetrix, Inc. (0.81%), Plus Therapeutics, Inc. (1.11%), Vivos Therapeutics, Inc. (0.81%), Encision Inc. (0.00%), Vapotherm, Inc. (9.92%), ProSomnus, Inc. (1.18%), Avinger, Inc. (3.64%), Minerva Surgical, Inc. (92.12%), Intelligent Bio Solutions Inc. (2.53%), Sharps Technology, Inc. (1.61%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Arch Therapeutics stock? Short selling ARTH is an investing strategy that aims to generate trading profit from Arch Therapeutics as its price is falling. ARTH shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arch Therapeutics? A short squeeze for Arch Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ARTH, which in turn drives the price of the stock up even further. How often is Arch Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ARTH, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: NURO Short Interest PSTV Short Interest VVOS Short Interest ECIA Short Interest VAPO Short Interest OSA Short Interest AVGR Short Interest UTRS Short Interest INBS Short Interest STSS Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:ARTH) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchYour Money is Not SafeAmerican AlternativeOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts